[ad_1]
VANCOUVER and MINNEAPOLIS – 
announced that company management will be participating in the 2021 H.C.
Wainwright Global Life Sciences Conference that is scheduled to take place
March 9-10, 2021. A recorded presentation by Bill Little, Neovasc’s Chief
Operating Officer, will be available on the Conference website starting at 7:00
am EST on March 9. Company management will also be scheduling one-on-one
meetings with investors; meetings may be requested through H.C. Wainwright.
A link to the recorded
presentation will also be available in the investor relations section of the
Neovasc website at https://www.neovasc.com/investors/.
About Neovasc Inc.
Neovasc is a specialty medical
device company that develops, manufactures and markets products for the rapidly
growing cardiovascular marketplace. The Company is a leader in the development
of minimally invasive transcatheter mitral valve replacement technologies, and
minimally invasive devices for the treatment of refractory angina. Its products
include the Neovasc Reducer™, for the treatment of refractory angina, which is
not currently commercially available in the United States (2 U.S. patients have
been treated under Compassionate Use) and has been commercially available in
Europe since 2015, and Tiara™, for the transcatheter treatment of mitral valve
disease, which is currently under clinical investigation in the United States,
Canada, Israel and Europe. For more information, visit: www.neovasc.com.
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.677.1839
Sean.Leous@icrinc.com
Forward-Looking Statement
Disclaimer
Certain statements in this news
release contain forward-looking statements within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws that may not be based on historical fact. When used herein,
the words “expect”, “anticipate”, “estimate”,
“may”, “will”, “should”, “intend,”
“believe”, and similar expressions, are intended to identify
forward-looking statements. Forward-looking statements may involve, but
are not limited to the expansion of its product range and the growing
cardiovascular marketplace. Forward-looking statements are based on estimates
and assumptions made by the Company in light of its experience and its
perception of historical trends, current conditions and expected future developments,
as well as other factors that the Company believes are appropriate in the
circumstances. Many factors could cause the Company’s actual results,
performance or achievements to differ materially from those expressed or
implied by the forward-looking statements, including those described in the
“Risk Factors” section of the Company’s Annual Report on Form 20-F
and in the Management’s Discussion and Analysis for the three and nine months
ended September 30, 2020 (copies of which may be obtained at www.sedar.com or www.sec.gov).
These factors should be considered carefully, and readers should not place
undue reliance on the Company’s forward-looking statements. The Company has no
intention and undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
[ad_2]